Your institution may have access to this item. Find your institution then sign in to continue.
Title
From the FDA.
Abstract
The article reports on developments relevant to drug-safety regulations by the U.S. Food and Drug Administration (FDA) in 2006. Key issues discussed include warnings from the FDA on the overall risk of liver damage toxicity from the use of pemoline and the issuance by the agency of an approval letter for the marketing of modafinil tablets by Cephalon Inc.